BR9807112A - Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato - Google Patents

Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato

Info

Publication number
BR9807112A
BR9807112A BR9807112-2A BR9807112A BR9807112A BR 9807112 A BR9807112 A BR 9807112A BR 9807112 A BR9807112 A BR 9807112A BR 9807112 A BR9807112 A BR 9807112A
Authority
BR
Brazil
Prior art keywords
combination
antigen
methotrexate
pharmaceutical formulation
treatment
Prior art date
Application number
BR9807112-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Howard L Weiner
Ahmad Al-Sabbagh
Patricia A Nelson
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of BR9807112A publication Critical patent/BR9807112A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes
BR9807112-2A 1997-01-24 1998-01-26 Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato BR9807112A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (fr) 1997-01-24 1998-01-26 Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate

Publications (1)

Publication Number Publication Date
BR9807112A true BR9807112A (pt) 2001-09-18

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807112-2A BR9807112A (pt) 1997-01-24 1998-01-26 Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato

Country Status (10)

Country Link
EP (1) EP0994717A4 (fr)
JP (1) JP2001511134A (fr)
KR (1) KR20000070460A (fr)
AU (1) AU6648898A (fr)
BR (1) BR9807112A (fr)
CA (1) CA2278152A1 (fr)
HU (1) HUP0001960A2 (fr)
IL (1) IL131025A0 (fr)
NO (1) NO993600L (fr)
WO (1) WO1998032451A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040103930A (ko) 2002-02-11 2004-12-09 앤태어스 파머, 인코퍼레이티드 피내 주사기
BRPI0614025A2 (pt) 2005-01-24 2012-12-25 Antares Pharma Inc injetores de jato
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
EP2268342B1 (fr) 2008-03-10 2015-09-16 Antares Pharma, Inc. Dispositif de sécurité pour injecteur
JP5611208B2 (ja) 2008-08-05 2014-10-22 アンタレス・ファーマ・インコーポレーテッド 多数回服用量の注射装置
AU2010226442A1 (en) 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
EP2582373A4 (fr) 2010-06-16 2013-10-30 Bruce Chandler May Utilisation de la lévocétirizine et du montélukast dans le traitement de la grippe, du rhume et d'une inflammation
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
JP6165786B2 (ja) 2012-03-06 2017-07-19 アンタレス・ファーマ・インコーポレーテッド 離脱力特徴を備える充填シリンジ
CN104487114A (zh) 2012-04-06 2015-04-01 安塔雷斯药品公司 针头辅助喷射注射给予睾酮组合物
WO2013169800A1 (fr) 2012-05-07 2013-11-14 Antares Pharma, Inc. Dispositif d'injection ayant un ensemble piston à came
EP2953667B1 (fr) 2013-02-11 2019-10-23 Antares Pharma, Inc. Dispositif d'injection à jet assistée par aiguille ayant une force de déclenchement réduite
WO2014164786A1 (fr) 2013-03-11 2014-10-09 Madsen Patrick Injecteur de dose avec système à pignon
WO2014165136A1 (fr) 2013-03-12 2014-10-09 Antares Pharma, Inc. Seringues pré-remplies à volume constant et leurs trousses
CA2901413A1 (fr) 2013-03-13 2014-10-09 Bruce Chandler May Utilisation de levocetirizine et de montelukast dans le traitement de la vascularite
RU2672871C2 (ru) 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Применение левоцетиризина и монтелукаста при лечении травматических повреждений
RU2015134423A (ru) * 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
EP3193875B1 (fr) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258065T1 (de) * 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
WO1992004049A1 (fr) * 1990-09-06 1992-03-19 Rijksuniversiteit Te Utrecht Inhibiteurs de la reponse de lymphocytes et de maladies immunitaires
BR9306042A (pt) * 1992-02-28 1997-11-18 Autoimmune Inc Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
WO1996040235A1 (fr) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Procede d'utilisation de superantigenes pour cibler des sous-populations de lymphocytes t
EP0834321B1 (fr) * 1995-06-13 2003-05-02 Nippon Meat Packers, Inc. Medicament a administration par voie orale contre la polyarthrite rhumatoide et aliment fonctionnel

Also Published As

Publication number Publication date
NO993600L (no) 1999-09-23
IL131025A0 (en) 2001-01-28
NO993600D0 (no) 1999-07-23
AU6648898A (en) 1998-08-18
HUP0001960A2 (hu) 2000-10-28
EP0994717A1 (fr) 2000-04-26
CA2278152A1 (fr) 1998-07-30
EP0994717A4 (fr) 2000-07-26
JP2001511134A (ja) 2001-08-07
KR20000070460A (ko) 2000-11-25
WO1998032451A1 (fr) 1998-07-30

Similar Documents

Publication Publication Date Title
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
BR9815255A (pt) Toxina de botulismo modificada, vacina oralcontra o botulismo, vacina oral contra umantìgeno selecionado e método para ministraroralmente um agente terapêutico a um animal
FR2719999B1 (fr) Composition pharmaceutique à base de gomme de guar et d'un antiacide neutralisant, à laquelle peut être ajoutée une série de principes actifs thérapeutiques.
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
BR9809951A (pt) Método para tratamento da obesidade
BR122012014331A8 (pt) Formulações farmacêuticas
ZA9432B (en) Use of anticonvulsants in the treatment of Parkinson's Disease and Parkinsonian Syndromes
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
CA2408537A1 (fr) Traitement du syndrome ou de la maladie du colon irritable
SI1073456T1 (sl) Uporaba osteoprotegerina za preventivo pred kardiovaskularnimi boleznimi in za njihovo zdravljenje
BR0012444A (pt) Composições de pó seco
CA2433833A1 (fr) Utilisation de flumazenil dans l'elaboration d'un medicament visant a traiter la dependence a l'alcool
CA2038744A1 (fr) Composition pharmaceutique contenant un medicament legerement hydrosoluble
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
ES2109234T3 (es) Metodo de tratamiento de la uveorretinitis autoinmune en el hombre.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]